Trial · NCT07901803
Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma
NCT07901803, Phase 2, Not yet recruiting, Washington University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma. Trials, record NCT07901803. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07901803
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma
- NCT number
- NCT07901803
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck Squamous Cell Carcinoma, Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- Aspirin, Paclitaxel
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | Start of treatment through completion of treatment or time of disease progression (total estimated time: 12 months) | ORR is defined as the proportion of participants achieving a confirmed complete response (CR) or partial response (PR) as their best overall response according to RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. |
| Secondary | Incidence of protocol-specified subset of adverse events (AEs) as assessed by CTCAE v6.0 | Start of treatment through 28 days after completion of treatment (total estimated time: 13 months) | Protocol-specified subset of AEs include AEs outside of those listed as follows: nausea, vomiting, fatigue, anemia, white blood cell decreased, neutrophil count decreased, thrombocytopenia, peripheral sensory neuropathy, peripheral motor neuropathy, infusion related reaction, bleeding/hemorrhage, weight loss, anorexia, edema, diarrhea, mucositis oral, arthralgia, and myalgia. For participants experiencing the same AE more than once, the maximum observed grade will be used in participant-level summaries. |
| Secondary | Duration of Response (DOR) | Time of CR or PR to time of disease progression or death from any cause, whichever occurs first (total estimated time: 4 years) | DOR is defined as the time from the first documented complete response (CR) or partial response (PR) to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. Participants who are alive without documented progression will be censored at the date of their last follow-up. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. |
| Secondary | Progression-free survival (PFS) | Date of first paclitaxel dose until disease progression or death from any cause (total estimated time: 4 years) | PFS is defined as the time from the first dose of paclitaxel to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. Participants who are alive without documented progression will be censored at the date of their last follow-up. |
| Secondary | Overall Survival (OS) | Date of first paclitaxel dose to death from any cause (total estimated time: 4 years) | OS is defined as the time from the first dose of paclitaxel to death from any cause. Participants who are alive at the time of analysis will be censored at the date of their last follow-up. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07901803
GET https://conductscience.org/api/trials/v1/NCT07901803/registered